NASDAQ:MYGN - Myriad Genetics Stock Price, Forecast & News

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Myriad Genetics, Inc. (NASDAQ:MYGN) released its earnings results on Monday, November, 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.26 by $0.18. The firm earned $186.30 million during the quarter, compared to analysts' expectations of $202.34 million. Myriad Genetics had a positive return on equity of 6.48% and a negative net margin of 1.83%. The company's revenue was down 7.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.43 earnings per share. View Myriad Genetics' Earnings History.

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Myriad Genetics.

Myriad Genetics updated its FY20 earnings guidance on Monday, November, 4th. The company provided EPS guidance of $1.00-1.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.78. The company issued revenue guidance of $800-810 million, compared to the consensus revenue estimate of $872.74 million.

7 brokerages have issued 1 year price objectives for Myriad Genetics' stock. Their forecasts range from $18.00 to $36.00. On average, they expect Myriad Genetics' stock price to reach $27.66 in the next twelve months. This suggests that the stock has a possible downside of 3.7%. View Analyst Price Targets for Myriad Genetics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 2 sell ratings, 4 hold ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Myriad Genetics.

Press coverage about MYGN stock has trended positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Myriad Genetics earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Myriad Genetics.

Myriad Genetics saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 13,670,000 shares, an increase of 32.1% from the December 15th total of 10,350,000 shares. Based on an average daily volume of 989,300 shares, the days-to-cover ratio is currently 13.8 days. Currently, 18.9% of the shares of the stock are short sold. View Myriad Genetics' Current Options Chain.

Some companies that are related to Myriad Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), NVIDIA (NVDA), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Advanced Micro Devices (AMD), Alibaba Group (BABA), Incyte (INCY), Kratos Defense & Security Solutions (KTOS), STMicroelectronics (STM) and Gilead Sciences (GILD).

Myriad Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.08%), Ingalls & Snyder LLC (0.04%), Louisiana State Employees Retirement System (0.03%), 6 Meridian (0.03%), Traverso Chambers Private Wealth Management LLC (0.02%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Myriad Genetics stock include Bernard Tobin, Dennis Langer, Gary A King, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard Bryan Riggsbee, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

MYGN stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Louisiana State Employees Retirement System and State of Alaska Department of Revenue. Company insiders that have sold Myriad Genetics company stock in the last year include Bernard Tobin, Gary A King, Ralph L Mcdade and Richard Bryan Riggsbee. View Insider Buying and Selling for Myriad Genetics.

MYGN stock was acquired by a variety of institutional investors in the last quarter, including Traverso Chambers Private Wealth Management LLC, 6 Meridian and Nisa Investment Advisors LLC. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson and Walter Phd Gilbert. View Insider Buying and Selling for Myriad Genetics.

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYGN stock can currently be purchased for approximately $28.72.

Myriad Genetics has a market capitalization of $2.14 billion and generates $851.10 million in revenue each year. The company earns $4.60 million in net income (profit) each year or $1.29 on an earnings per share basis. Myriad Genetics employs 2,600 workers across the globe.View Additional Information About Myriad Genetics.

The official website for Myriad Genetics is http://www.myriad.com/.

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]